Axitinib
Generated by NIH 3D workflows using data provided by
Kzoghebi
Created:
2/17/19
Submitted:
3/6/23
Published:
3/6/23
Select an image below to view
Category
Description
Axitinib is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.
